Skip to main content

Market Research Outlook

CDSCO Decoded · Issue 1 · November 2026

Every month we read the minutes of CDSCO’s Subject Expert Committees and pull out what matters for companies selling medicines in India: who was cleared to make and sell, whose biosimilar trial moved, and who was held back. Issue 1 covers the meetings held from 14 October to 12 November 2026.

5products recommended for manufacture and marketing
8Indian biosimilar or generic development files reviewed
2new pembrolizumab biosimilar files
9committee meetings read

Download this tracker as Excel

MRO View: Two signals stand out. The pembrolizumab biosimilar queue keeps growing ahead of the 2028 patent date, with Zydus and Shilpa Biologicals now on file. And the committee refused Sun Pharma a trial waiver for new semaglutide uses, a reminder that a cheap molecule still needs Indian data for each new indication.

Cleared to make and sell

The committee recommended permission to manufacture and market these products. A recommendation goes to the Drugs Controller General of India for the final decision.

CompanyProductPanel outcomeMeeting
CuraTeQ BiologicsDenosumab 60 mg/mL prefilled syringe and drug substance (biosimilar)Recommended for manufacture and marketingAnalgesics, rheumatology and orthopaedics, 5 Nov
BioGenomicsInsulin glargine 100 IU/mL (biosimilar)Recommended for manufacture and marketingEndocrinology and metabolism, 4 Nov
MSN LaboratoriesApalutamide 240 mg tablet (new strength)Recommended, with a Phase IV study conditionOncology, 5 Nov
Akums DrugsEplerenone + torsemide tabletsRecommended after BE study reviewCardiovascular, 4 Nov
Windlas BiotechNebivolol + telmisartan + cilnidipine bilayer tabletRecommended after Phase III reviewCardiovascular, 4 Nov

Indian biosimilar and generic development

CompanyProductPanel outcomeMeeting
Zydus LifesciencesPembrolizumab biosimilar ZRC 3323, Phase III against KeytrudaChanges to the trial design askedOncology, 28 Oct
Shilpa BiologicalsPembrolizumab biosimilarProtocol approved subject to changesOncology, 28 Oct
CuraTeQ BiologicsBevacizumab biosimilarChanges to the protocol askedOncology, 28 Oct
Enzene BiosciencesCetuximab biosimilarClarifications and documents askedOncology, 28 Oct
Intas PharmaceuticalsGolimumab biosimilar prefilled syringe, Phase 1/3Trial permitted with conditionsAnalgesics, rheumatology and orthopaedics, 5 Nov
Mankind PharmaInsulin degludec 100 units/mL, Phase ITrial permitted as presentedEndocrinology and metabolism, 22 Oct
Alkem LaboratoriesInsulin degludec 100 units/mLAsked to validate degludec specific test kitsEndocrinology and metabolism, 4 Nov
Zydus LifesciencesCapivasertib 160 mg and 200 mg tabletsBE study and Phase III permitted; BE report to be reviewed firstOncology, 5 Nov

Held back

CompanyProductPanel outcomeMeeting
Sun PharmaSemaglutide injection for additional indicationsPhase III trial waiver not recommendedEndocrinology and metabolism, 4 Nov
Amneal PharmaceuticalsEliglustat sublingual filmMore data askedEndocrinology and metabolism, 4 Nov
Entod PharmaceuticalsLosartan eye drops, 0.4 and 0.8 mg/mL, Phase IIProtocol changes asked: dosing that allows adequate sleep, and added dry eye testsOphthalmology, 14 Oct

Vaccine trials

Indian vaccine makers dominated the two vaccine committee meetings, with four of six proposals sent back for protocol changes or cleared only on a revised design.

CompanyProductPanel outcomeMeeting
Biological ELiquid hexavalent vaccine (DTwP, hepatitis B, IPV, Hib), Phase III booster doseRevised protocol asked, limited to the booster doseVaccines, 29 Oct
Indian ImmunologicalsHepatitis B vaccine (rDNA), Phase IIIRevised protocol asked; sample size for lot to lot consistency found inadequateVaccines, 29 Oct
MSD PharmaceuticalsHuman papillomavirus 9 valent vaccine, recombinantStudy permitted as per the submitted protocolVaccines, 29 Oct
Syngene InternationalMynflu001, recombinant adjuvanted influenza vaccine, Phase IPhase I trial permitted on the revised protocolVaccines, 29 Oct
Serum Institute of IndiaBivalent typhoid conjugate vaccine, Phase IIIRevised protocol askedVaccines, 29 Oct
Human Biologicals Institute (Indian Immunologicals)Live attenuated Zika vaccine, freeze dried, Phase IPhase I trial permitted as presentedVaccines, 12 Nov

Innovator trials and label changes

CompanyProductPanel outcomeMeeting
AstraZenecaSaruparib, Phase IIITrial permittedOncology, 5 Nov
AstraZenecaLaroprovstat with rosuvastatin, Phase IIITrial permittedCardiovascular, 4 Nov
AstraZenecaAZD6234Trial permittedEndocrinology and metabolism, 4 Nov
NovartisPacibekitug, Phase IIITrial permittedCardiovascular, 4 Nov
NovartisFWY003, Phase ITrial permitted with conditions, including heart checks before enrolmentOphthalmology, 14 Oct
AbbVieVenetoclax with acalabrutinib in untreated CLLLabel update recommendedOncology, 5 Nov
RochePhesgoUpdated prescribing information approvedOncology, 28 Oct

What this means for market entry

  • Pembrolizumab: count the Indian developers, not the patent date. See the patent expiry calendar.
  • Insulins: degludec is the next biosimilar race, with Mankind and Alkem both in the trial pathway and glargine still drawing new entrants.
  • Denosumab: a third Indian maker is close to market after Enzene and Zydus. See the drug market entry tracker.

Panel outcomes are summarised from the published SEC recommendations. A recommendation is not a final approval. Source: Market Research Outlook · Last reviewed: 17 Nov 2026 · How we verify

Get the monthly India tracker updateNew state data and new plant announcements in one short email, once a month.

One email a month. Reply to any email to unsubscribe. Privacy policy

Frequently asked questions

What is a CDSCO Subject Expert Committee?

An expert panel that reviews new drug, biosimilar and trial applications and advises the Drugs Controller General of India, who takes the final decision.

How often is CDSCO Decoded published?

Monthly, after the committee minutes for the month are released.

Download this tracker as Excel

Every row on this page in one spreadsheet, ready to filter and share with your team. Free for internal use.

We use your details only to share related MRO research. See our privacy policy.

Want a filing watched for you?

We track CDSCO panels for your molecule and competitors and tell you when a rival moves.